Personalized Medical Care & Dedicated International Patient Concierge

4.9 Patient Satisfaction

en-US

Medical Clinic LogoMedical ClinicHome
Book Consultation
Book Consultation
Patient Guide
SpecialtiesServicesDoctorsOffersArticlesBefore & AfterReviewsAbout UsContact Us
PDRN (Placentex) Regenerative Injection: What to Know

Medical Guide

PDRN (Placentex) Regenerative Injection: What to Know

PDRN (Placentex) is a salmon-DNA injection used for joint pain. Learn how polydeoxyribonucleotide works, its limited evidence, and US regulatory status.

Schedule a Consultation

PDRN (Placentex) Regenerative Injection: What to Know

Medically reviewed by Dr. Heejun Kim, Board-Certified Orthopedic Surgeon, Chief Director, Nucellin Orthopedic Clinic

If you have been researching non-surgical options for stubborn joint pain, you may have come across PDRN, sometimes referred to by the brand name Placentex. It is one of several regenerative-oriented injectables discussed in orthopedic and sports-medicine circles, and it often gets grouped together with platelet-rich plasma (PRP) and polynucleotide (PN) products. But PDRN is its own distinct material with its own mechanism, its own body of evidence, and its own regulatory status that differs significantly between countries.

This article explains what PDRN is, what it is thought to do inside a joint, how it compares with a conventional steroid injection, and what the current evidence does and does not support. Just as importantly, it is honest about the limits: the evidence base is still emerging, results vary from person to person, and PDRN is not approved by the U.S. Food and Drug Administration (FDA). At Nucellin Orthopedic Clinic in Yongsan-gu, Seoul, this kind of care is delivered under Korean medical regulation rather than U.S. regulation, and candidacy is always determined by a hands-on examination rather than by an article on the internet.

What Is PDRN (Placentex)?

PDRN stands for polydeoxyribonucleotide. It is a mixture of DNA fragments that are typically purified from the sperm cells or gonadal tissue of fish, most commonly salmon or trout. Because the DNA fragments in commercial PDRN products share a high degree of similarity with human DNA, the material is considered highly purified and low in the proteins that could otherwise trigger a strong immune reaction. In practice, PDRN is best thought of as a salmon DNA extract injection rather than as a drug in the traditional small-molecule sense.

Placentex is a brand of PDRN. Nucellin Orthopedic Clinic uses what it describes as authentic Italian Placentex, referring to a PDRN product manufactured and authorized in Italy and various other countries outside the United States. It is worth emphasizing what "authorized in some countries" means and does not mean. It means a national or regional regulator has permitted the product to be sold there under its own rules. It does not mean the product carries FDA approval or FDA clearance, and it does not automatically translate into approval anywhere else.

One point of frequent confusion is the word "placenta." Despite the brand name Placentex, the polydeoxyribonucleotide in these products is derived from fish DNA, not from human or animal placenta. The naming reflects marketing history more than biological content. When you evaluate any PDRN Placentex injection, the relevant question is the source and purity of the polydeoxyribonucleotide itself.

How PDRN Injection Is Thought to Work

The proposed mechanisms behind a polydeoxyribonucleotide injection joint therapy are drawn largely from laboratory and preclinical research, and they should be read as proposed rather than proven for every clinical use. Two mechanisms are discussed most often.

The first is the so-called salvage pathway. When cells build new DNA, they can either synthesize the building blocks from scratch or recycle existing fragments. The DNA fragments in PDRN are thought to supply ready-made nucleotides that cells can use through this salvage pathway, potentially supporting tissue that is under metabolic stress. The second, and more frequently cited, mechanism involves the adenosine A2A receptor. PDRN is believed to interact with this receptor, which has been associated in laboratory studies with anti-inflammatory signaling, improved local blood-vessel formation, and support for tissue repair processes.

Because of these proposed actions, PDRN is often described as a non-steroid regenerative injection. The framing matters: rather than simply suppressing inflammation the way a corticosteroid does, PDRN is intended to influence the local biological environment in a way that may support repair. That is the theory. Whether these mechanisms translate into meaningful, durable clinical benefit for a given joint problem is a separate question, and the honest answer is that the evidence is still limited and results vary. No injection should be presented as a way to regrow cartilage or reverse arthritis, and PDRN is no exception.

PDRN vs Steroid Injection

Many patients arrive already familiar with corticosteroid ("cortisone") injections, so a PDRN vs steroid injection comparison is a natural starting point. The two are not interchangeable, and each has a different role.

A corticosteroid injection is a potent anti-inflammatory. It can provide meaningful short-term relief for a flare of joint or soft-tissue inflammation, often within days. Its limitations are also well documented: the relief is frequently temporary, repeated injections into the same joint carry recognized risks, and steroids do not aim to support tissue repair. In some settings, frequent steroid use has been associated with potential harm to nearby tissue over time.

PDRN, by contrast, is a non-steroidal material intended to support the local repair environment rather than to deliver a rapid anti-inflammatory hit. In principle, that means any benefit may build more gradually and may involve a short series of injections rather than a single shot. It also means PDRN is not the right tool when the clinical goal is to calm an acute, severe inflammatory flare quickly. Neither option is universally "better." The appropriate choice depends on the diagnosis, the stage of the condition, prior treatments, and individual factors that only a physician can weigh during an examination. It is also worth noting that a corticosteroid injection is a widely used, established option, whereas PDRN for joints sits in a more emerging, less standardized category.

What the Evidence Shows for Joints

Interest in PDRN regenerative therapy Korea and elsewhere has grown alongside a modest but expanding research literature. Several small studies and early trials have explored intra-articular PDRN, particularly for knee osteoarthritis, and some have reported reductions in pain and improvements in function compared with baseline or with certain comparators. This is genuinely encouraging as a signal, and it is why the therapy is discussed seriously by clinicians who work in regenerative orthopedics.

At the same time, the evidence should be described accurately. Many of the available studies are small, vary in how they were designed, use different injection protocols, and follow patients for relatively short periods. High-quality, large, long-term randomized trials that would allow strong, definitive conclusions are still limited. That combination, promising early signals paired with limited high-level evidence, is exactly why responsible clinicians avoid guarantees. The honest summary is that some studies suggest intra-articular PDRN may reduce knee-osteoarthritis pain and improve function for some people, that the evidence is emerging rather than settled, and that outcomes vary. Anyone who promises a cure, permanent relief, or a pain-free result is overstating what the science currently supports.

Regulatory Status: Not FDA-Approved in the US

This is the single most important point for any U.S.-based reader to understand. PDRN, including Placentex, is not FDA-approved in the United States for orthopedic or joint use. Any use of PDRN in the U.S. would be off-label, and products obtained outside a regulated supply chain carry additional concerns because their quality, purity, and sterility cannot be assumed or guaranteed.

The fact that Placentex is authorized in Italy and various other countries does not equal FDA approval. Regulatory approval is country-specific. A product can be lawfully sold in one jurisdiction and simultaneously have no approval in another. When care involving PDRN is provided at Nucellin Orthopedic Clinic, it is delivered under Korean medical regulation, not under U.S. FDA rules. For patients traveling from the United States, that distinction has real implications: the oversight framework, the product authorization, and the standards that apply are Korean, and this care would not typically be covered by U.S. insurance. None of this makes the treatment inappropriate in its own setting, but it is essential information for making an informed decision, and it is why transparent disclosure of regulatory status is part of how the clinic communicates about these therapies. You can read more about the clinic's approach on the Nucellin Orthopedic Clinic website.

What to Expect During Evaluation and Treatment

A responsible pathway to any regenerative injection starts with diagnosis, not with the injection itself. That usually means a detailed history, a physical examination, and appropriate imaging. Imaging tools such as X-ray, ultrasound, and MRI are diagnostic instruments used to understand the joint; they are not treatments. In many cases, ultrasound or fluoroscopy may also be used to help guide an injection accurately into the intended target.

Conservative measures come first for most joint problems. Activity modification, physical therapy, weight management where relevant, and appropriate use of established treatments are typically considered before, or alongside, regenerative options. If a PDRN course is considered appropriate, it may be planned as a short series rather than a single injection, and expectations should be framed honestly: PDRN aims to support the local environment, benefit is not guaranteed, and it does not replace surgery when surgery is genuinely indicated. Non-surgical care can be a reasonable choice for many people, but choosing a non-surgical path does not guarantee that surgery will be avoided in the future. To ask questions specific to your situation, you can reach the clinic's English-speaking coordinator through the Nucellin contact page.

Who Might Be a Candidate

There is no universal checklist that determines candidacy for a salmon DNA extract injection, and no article can tell you whether it is right for you. Broadly, people who are sometimes considered for regenerative injections include those with mild-to-moderate joint symptoms who have not achieved adequate relief from conservative care, who understand the emerging nature of the evidence, and who have realistic expectations. Candidacy also depends on ruling out conditions where an injection would be inappropriate, on overall health, and on the specific joint involved.

Ultimately, whether PDRN is a reasonable option for a given individual is a decision made after an in-person examination and diagnosis. A physician can only recommend a treatment responsibly once the underlying problem is properly understood. As Chief Director, Dr. Heejun Kim is a board-certified orthopedic surgeon (a Korean credential) whose background includes training in orthopedic surgery at Severance Hospital, Yonsei University; he is also a regular member of numerous Korean and international orthopedic and regenerative-medicine societies, including the International Society for Medical Shockwave Treatment (ISMST).

Risks and Limitations

Like any injection, PDRN carries the general risks associated with introducing a needle and material into a joint or soft tissue, including temporary pain or swelling at the site, bruising, and a small risk of infection. Beyond these general risks, the specific limitations of PDRN deserve emphasis. The evidence base is still limited, injection protocols are not standardized, long-term data are sparse, and the product is not FDA-approved in the United States. Product quality and sterility are only as reliable as the supply chain and the regulatory framework behind them, which is one reason the source of the product matters.

The most important limitation, however, is one of expectations. PDRN is not a cure, it does not guarantee pain relief, and it should never be described as something that regrows cartilage or reverses arthritis. It is one possible tool, with emerging evidence, that a qualified physician may consider as part of an individualized, conservative-first plan. Results vary, and honesty about that is a feature of good care, not a weakness.

Frequently Asked Questions

Is PDRN the same as PRP?

No. PRP (platelet-rich plasma) is prepared from your own blood and concentrates your platelets and growth factors, so it is autologous. PDRN is a purified DNA fragment product derived from fish, most often salmon, and is not made from your blood. They are different materials with different mechanisms, and a physician can explain which, if either, may suit your situation.

Is PDRN a steroid?

No. PDRN is a non-steroid regenerative injection. Unlike a corticosteroid, which primarily suppresses inflammation, PDRN is intended to support the local repair environment. Because they work differently, they are not interchangeable, and the right choice depends on your diagnosis.

Is Placentex approved by the FDA?

No. Placentex and PDRN more generally are not FDA-approved in the United States for joint or orthopedic use. Placentex is authorized in Italy and some other countries, but that is not the same as FDA approval. At Nucellin Orthopedic Clinic, this care is delivered under Korean medical regulation.

Does PDRN regrow cartilage or cure arthritis?

No. There is no credible basis for claiming that PDRN regrows cartilage, cures arthritis, or provides permanent, pain-free results. Some studies suggest it may reduce pain and improve function for some people with knee osteoarthritis, but the evidence is limited and results vary.

How many injections are needed?

There is no fixed answer, and protocols are not standardized. PDRN is often given as a short series rather than a single injection, but the specifics depend on the joint, the diagnosis, and the treating physician's assessment. Any plan should be individualized after an examination.

Will my U.S. insurance cover PDRN?

Generally, no. Elective regenerative orthopedic treatments such as PDRN are typically not covered by U.S. insurance, and because the therapy is provided in Korea under Korean regulation, U.S. coverage should not be assumed. Confirm any financial questions directly with the clinic.

Is PDRN safe?

PDRN carries the usual risks of any injection, such as temporary soreness, swelling, bruising, or a small infection risk, and its safety also depends on product quality and proper technique. Because it is not FDA-approved in the U.S., the regulatory framework that applies is Korean. A physician should review your health history before recommending it.

The Bottom Line

  • PDRN (Placentex) is a purified polydeoxyribonucleotide, typically derived from salmon or trout DNA, and it is a non-steroid material used in regenerative-oriented injections.
  • It is not FDA-approved in the United States; Placentex is authorized in some other countries, and at Nucellin Orthopedic Clinic this care is delivered under Korean regulation, not U.S. regulation.
  • Some studies suggest intra-articular PDRN may reduce knee-osteoarthritis pain and improve function, but the evidence is emerging and limited, and results vary.
  • PDRN is not a steroid, not a cure, and does not regrow cartilage or guarantee a pain-free outcome.
  • Candidacy is determined by an in-person examination and diagnosis, with conservative measures generally considered first.

This article is for general educational purposes only and is not a self-diagnosis tool. It cannot replace an in-person evaluation, diagnosis, or personalized medical advice from a qualified clinician. Regenerative injections such as PDRN are not FDA-approved in the United States, and any care described here is delivered at Nucellin Orthopedic Clinic under Korean medical regulation rather than U.S. FDA oversight. Outcomes vary from person to person, and no result is guaranteed. Whether any treatment is appropriate for you can only be determined through a professional examination.

More Articles

Continue reading our clinical guides.

View All

Learn More

Learn More

Medical Clinic

Dedicated to evidence-based medical care, personalized treatment planning, and comprehensive support for local and international patients.

Treatments

SpecialtiesServicesMedical TeamSpecial OffersMedical Articles

Patient Guide

About UsHow It WorksBefore & AfterPatient ReviewsPress & Media

Information & Legal

Contact & LocationSite SearchPrivacy PolicyRefund & Cancellation PolicyTerms of Use

© Medical Clinic. All rights reserved.

Individual clinical results may vary. Please consult a board-certified specialist.